AstraZeneca invests £1.5bn into US firm Summit for cancer drug tie-up
The firms will collaborate on Summit’s experimental new medicine as well as researching how it could be combined with Astra’s treatments.
The firms will collaborate on Summit’s experimental new medicine as well as researching how it could be combined with Astra’s treatments.
Select a language and narrator voice before playback.